SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence
International Journal of Hepatology · 2026-01 · 2026 (1)
DOI: 10.1155/ijh/7257876 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Hepatology, online erschienen am 24.06.2026. Verfasst von Abdallah Al Ghnaimat und 12 weiteren Autor:innen. Beteiligte Einrichtung: Faculty of Medicine, Hashemite University, Zarqa, Jordan, hu.edu.jo. Die Arbeit wurde bisher 2-mal zitiert (Crossref) und nennt 30 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Goal The goal is to systematically evaluate the efficacy and safety of SGLT‐2 inhibitors (SGLT2i) versus standard therapy for ascites management in liver cirrhosis.
Background
SGLT2i promote natriuresis and osmotic diuresis, offering potential therapeutic benefits for fluid overload in cirrhosis, similar to their established role in heart failure. However, high‐quality comparative evidence remains limited. Study A systematic search of PubMed, Scopus, Cochrane, Embase, and Web of Science was conducted through October 2025 following PRISMA 2020 guidelines. Eligible studies included randomized controlled trials and prospective comparative studies enrolling adults (≥ 18 years) with confirmed cirrhosis treated with dapagliflozin or empagliflozin, alone or alongside standard therapy, versus placebo or standard care for ≥ 2 weeks. The primary outcome was complete ascites resolution; secondary outcomes included mortality, body weight, eGFR, and serum creatinine and sodium levels.
Results
Three studies (two RCTs and one prospective trial; n = 382) were included, comprising 241 patients receiving SGLT2i and 141 controls. SGLT2i significantly increased complete ascites resolution (OR: 2.39, 95% CI: 1.47–3.90; p < 0.001; I 2 = 15 % ) and reduced body weight (MD: −4.86 kg, 95% CI: −7.57 to −2.14; p = 0.0005; I 2 = 0 % ). No significant differences were observed in eGFR, serum creatinine, serum sodium, or mortality within the RCT subgroup (OR: 1.60, 95% CI: 0.53–4.87; I 2 = 0 % ); the overall three‐study pool (OR: 0.27, 95% CI: 0.13–0.56; I 2 = 87 % ) was driven by the nonrandomized trial (test for subgroup differences p = 0.001). The only placebo‐controlled RCT reported significantly higher rates of AKI (50% vs. 15%, p = 0.04) and infections (55% vs. 20%, p = 0.04) in the SGLT2i arm.
Conclusions
SGLT2i improved ascites resolution and body weight without changes in routinely measured renal parameters, but unresolved AKI and infection signals and very low GRADE certainty for mortality preclude routine clinical use. SGLT2i should be considered only as individualized investigational therapy under close monitoring pending larger RCTs. PROSPERO (CRD420261303781).
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Faculty of Medicine, Hashemite University, Zarqa, Jordan, hu.edu.jo.
- Faculty of Medicine, Beni-Suef University, Beni-Suef, Egypt, bsu.edu.eg.
- Faculty of Pharmacy, İstinye University, İstanbul, Turkey.
- Faculty of Medicine, Cairo University, Cairo, Egypt, cu.edu.eg.
- Faculty of Medicine, Zagazig University, Zagazig, Egypt, zu.edu.eg.
- Faculty of Medicine, 21 September University for Medical and Applied Sciences, Sana'a, Yemen.
ORCID-Profile: Abdallah Al Ghnaimat, Nour Aldin T Ahmed, Omar Mahmood Al-Azzawi, EzzElDien A Ibrahim, Roaa Rayyan, Souheb Alkloub, Ekram Al Joufi, Ezz Eldein Breish, Sana Shaik, Noorhan Al-Kadhimi, Batool Al Masalha, Hossam Abdelbaqi, Dalia Atef Abouda
Zitieren
APA
Al Ghnaimat, A., Ahmed, N. A. T., Al-Azzawi, O. M., Ibrahim, E. A., Rayyan, R., Alkloub, S., Al Joufi, E., Breish, E. E., Shaik, S., Al-Kadhimi, N., Al Masalha, B., Abdelbaqi, H., & Abouda, D. A. (2026). SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence. International Journal of Hepatology, 2026(1). https://doi.org/10.1155/ijh/7257876
Vancouver
Al Ghnaimat A, Ahmed NAT, Al-Azzawi OM, Ibrahim EA, Rayyan R, Alkloub S, et al. SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence. International Journal of Hepatology. 2026;2026(1). doi:10.1155/ijh/7257876
BibTeX
@article{AlGhnaimat2026,
author = {Al Ghnaimat, Abdallah and Ahmed, Nour Aldin T and Al-Azzawi, Omar Mahmood and Ibrahim, EzzElDien A and Rayyan, Roaa and Alkloub, Souheb and Al Joufi, Ekram and Breish, Ezz Eldein and Shaik, Sana and Al-Kadhimi, Noorhan and Al Masalha, Batool and Abdelbaqi, Hossam and Abouda, Dalia Atef},
title = {SGLT‐2 Inhibitors for Ascites Management in Liver Cirrhosis: A Systematic Review and Meta‐Analysis of Available Evidence},
journal = {International Journal of Hepatology},
year = {2026},
volume = {2026},
number = {1},
doi = {10.1155/ijh/7257876}
}
EUVIMED